Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Significant efficacy, minimal toxicity reported for radiosensitizing agent AK-2123

Sep. 27, 1999

New hematoporphyrins for photodynamic therapy of tumors in development in China

Sep. 27, 1999

French investigators continue research on homocamptothecins; dual Topo I and II inhibitor identified

Sep. 27, 1999

Chinese researchers design new norcantharidinimide derivatives as antitumor agents

Sep. 27, 1999

Phase I results of Bay-12-9566 presented at ECCO 10; Bayer halts all trials on the compound

Sep. 27, 1999

UT researchers uncover mechanism of chemopreventive activity of sulindac

Sep. 27, 1999

Novel karenitecin from BioNumerik inhibits Topo I and is synergistic with a TS inhibitor

Sep. 24, 1999

Stylostatin 2 available for licensing from ASU

Sep. 24, 1999

KRN-8602 studied as new agent for recurrent high-grade glioma

Sep. 24, 1999

New antitumor antibiotic discovered by Yamanouchi

Sep. 23, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...